News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Solvaldi Too Expensive? Not To Patients—Gilead Sciences, Inc. (GILD) Profit Triples On Strong Hep C Drug Sales


4/23/2014 8:24:41 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Gilead Sciences, Inc. announced today its results of operations for the quarter ended March 31, 2014. Total revenues for the first quarter of 2014 increased to $5.00 billion from $2.53 billion for the first quarter of 2013. Gilead Sciences Inc. (GILD), with a current value of $112.08B, started the session at $73.00. A quick look at the market, the company’s traded between $71.85 to $73.26 and has traded between $46.70 and $84.88 over the past year.

Help employers find you! Check out all the jobs and post your resume.

Read at News Release

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES